PACIRA BIOSCIENCES INC (PCRX)

US6951271005 - Common Stock

25.9  -0.91 (-3.39%)

After market: 25.9 0 (0%)

Fundamental Rating

6

PCRX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. PCRX has an excellent profitability rating, but there are some minor concerns on its financial health. PCRX is valued quite cheap, while showing a decent growth score. This is a good combination! With these ratings, PCRX could be worth investigating further for value investing!.



7

1. Profitability

1.1 Basic Checks

In the past year PCRX was profitable.
In the past year PCRX had a positive cash flow from operations.
PCRX had positive earnings in 4 of the past 5 years.
Each year in the past 5 years PCRX had a positive operating cash flow.

1.2 Ratios

PCRX's Return On Assets of 2.67% is amongst the best of the industry. PCRX outperforms 87.18% of its industry peers.
With an excellent Return On Equity value of 4.83%, PCRX belongs to the best of the industry, outperforming 87.18% of the companies in the same industry.
PCRX has a better Return On Invested Capital (4.02%) than 82.56% of its industry peers.
PCRX had an Average Return On Invested Capital over the past 3 years of 4.32%. This is significantly below the industry average of 16.40%.
Industry RankSector Rank
ROA 2.67%
ROE 4.83%
ROIC 4.02%
ROA(3y)1.88%
ROA(5y)3.15%
ROE(3y)4.21%
ROE(5y)6.6%
ROIC(3y)4.32%
ROIC(5y)4.07%

1.3 Margins

With an excellent Profit Margin value of 6.23%, PCRX belongs to the best of the industry, outperforming 86.15% of the companies in the same industry.
In the last couple of years the Profit Margin of PCRX has declined.
PCRX's Operating Margin of 12.94% is amongst the best of the industry. PCRX outperforms 86.15% of its industry peers.
In the last couple of years the Operating Margin of PCRX has grown nicely.
With a decent Gross Margin value of 72.65%, PCRX is doing good in the industry, outperforming 78.97% of the companies in the same industry.
PCRX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 12.94%
PM (TTM) 6.23%
GM 72.65%
OM growth 3Y-2.79%
OM growth 5Y20.05%
PM growth 3Y-43.17%
PM growth 5YN/A
GM growth 3Y-0.03%
GM growth 5Y-0.43%

6

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PCRX is destroying value.
Compared to 1 year ago, PCRX has more shares outstanding
PCRX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for PCRX has been reduced compared to a year ago.

2.2 Solvency

PCRX has an Altman-Z score of 1.89. This is not the best score and indicates that PCRX is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 1.89, PCRX is doing good in the industry, outperforming 68.72% of the companies in the same industry.
PCRX has a debt to FCF ratio of 3.75. This is a good value and a sign of high solvency as PCRX would need 3.75 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 3.75, PCRX belongs to the best of the industry, outperforming 89.23% of the companies in the same industry.
A Debt/Equity ratio of 0.59 indicates that PCRX is somewhat dependend on debt financing.
PCRX has a Debt to Equity ratio of 0.59. This is in the lower half of the industry: PCRX underperforms 64.62% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.59
Debt/FCF 3.75
Altman-Z 1.89
ROIC/WACC0.55
WACC7.37%

2.3 Liquidity

A Current Ratio of 5.24 indicates that PCRX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.24, PCRX is in the better half of the industry, outperforming 67.69% of the companies in the same industry.
PCRX has a Quick Ratio of 4.17. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.17, PCRX is in the better half of the industry, outperforming 61.03% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.24
Quick Ratio 4.17

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 12.74% over the past year.
The Earnings Per Share has been growing by 22.93% on average over the past years. This is a very strong growth
Looking at the last year, PCRX shows a small growth in Revenue. The Revenue has grown by 1.21% in the last year.
PCRX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.88% yearly.
EPS 1Y (TTM)12.74%
EPS 3Y9.9%
EPS 5Y22.93%
EPS growth Q2Q11.25%
Revenue 1Y (TTM)1.21%
Revenue growth 3Y16.25%
Revenue growth 5Y14.88%
Revenue growth Q2Q5.37%

3.2 Future

The Earnings Per Share is expected to grow by 12.07% on average over the next years. This is quite good.
The Revenue is expected to grow by 10.37% on average over the next years. This is quite good.
EPS Next Y-2.82%
EPS Next 2Y11.46%
EPS Next 3Y14.4%
EPS Next 5Y12.07%
Revenue Next Year2.34%
Revenue Next 2Y6.04%
Revenue Next 3Y7.08%
Revenue Next 5Y10.37%

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

8

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 8.87, which indicates a very decent valuation of PCRX.
Based on the Price/Earnings ratio, PCRX is valued cheaply inside the industry as 92.82% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 25.25, PCRX is valued rather cheaply.
The Price/Forward Earnings ratio is 9.13, which indicates a very decent valuation of PCRX.
PCRX's Price/Forward Earnings ratio is rather cheap when compared to the industry. PCRX is cheaper than 93.33% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of PCRX to the average of the S&P500 Index (21.67), we can say PCRX is valued rather cheaply.
Industry RankSector Rank
PE 8.87
Fwd PE 9.13

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 89.74% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 91.79% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 8.63
EV/EBITDA 8.38

4.3 Compensation for Growth

PCRX has a very decent profitability rating, which may justify a higher PE ratio.
PCRX's earnings are expected to grow with 14.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)0.39
EPS Next 2Y11.46%
EPS Next 3Y14.4%

0

5. Dividend

5.1 Amount

No dividends for PCRX!.
Industry RankSector Rank
Dividend Yield N/A

PACIRA BIOSCIENCES INC

NASDAQ:PCRX (4/24/2024, 3:02:45 PM)

After market: 25.9 0 (0%)

25.9

-0.91 (-3.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.20B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 8.87
Fwd PE 9.13
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)0.39
Profitability
Industry RankSector Rank
ROA 2.67%
ROE 4.83%
ROCE
ROIC
ROICexc
ROICexgc
OM 12.94%
PM (TTM) 6.23%
GM 72.65%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0.59
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 5.24
Quick Ratio 4.17
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)12.74%
EPS 3Y9.9%
EPS 5Y
EPS growth Q2Q
EPS Next Y-2.82%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)1.21%
Revenue growth 3Y16.25%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y